# Title
Synthesis O
of O
putative O
metabolites O
and O
investigation O
of O
the O
metabolic O
fate O
of O
gliclazide, B-Chemical
[1-(3-azabicyclo(3,3,0)oct-3-yl)-3-(4-methylphenylsulfonyl) B-Chemical
urea], I-Chemical
in O
diabetic B-Disease
patients. B-Species

# Abstract
Synthesis O
of O
postulated O
hydroxylated O
metabolites O
of O
gliclazide B-Chemical
is O
described O
together O
with O
their O
detailed O
structural O
analysis O
using O
1H-NMR, O
two-dimensional O
1H-NMR, O
and O
MS O
to O
characterize O
the O
products. O
Metabolism O
of O
gliclazide B-Chemical
has O
been O
investigated O
in O
the O
urine O
of O
nine O
patients B-Species
of O
different O
ethnic O
origins O
receiving O
gliclazide B-Chemical
therapy O
for O
the O
treatment O
of O
diabetes. B-Disease
Urine O
extracts O
were O
analyzed O
by O
GC O
MS O
to O
quantify O
and O
identify O
the O
metabolites O
excreted O
in O
urine O
and O
the O
metabolites O
compared O
with O
the O
synthesized O
products. O
Metabolic O
profiles O
in O
all O
diabetic B-Disease
patients B-Species
were O
very O
similar O
and O
comparable O
with O
those O
reported O
for O
healthy O
human O
volunteers. O
In O
addition O
to O
the O
expected O
metabolites O
arising O
from O
oxidation O
of O
the O
4-methylphenyl O
ring, O
four O
isomeric O
hydroxylated O
products O
of O
the O
azabicyclooctyl O
ring O
were O
identified O
and O
the O
structure O
of O
a O
fifth O
isomer O
postulated. O